Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/brca1-and-brca2-families-and-the-risk-of-skin-cancer-1WzBD1basP
References (53)
-
S. Sigurdsson, S. Thorlacius, J. Tomasson, L. Tryggvadottir, K. Benediktsdottir, J. Eyfjord, E. Jonsson (1997)
BRCA2 mutation in Icelandic prostate cancer patientsJournal of Molecular Medicine, 75
-
Liat Drucker, R. Stackievitz, B. Shpitz, S. Yarkoni (2000)
Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study.Anticancer research, 20 1B
-
D. Easton, J. Hopper, Duncan Thomas, A. Antoniou, P. Pharoah, A. Whittemore, R. Haile (2004)
Breast Cancer Risks for BRCA1/2 CarriersScience, 306
-
J. Struewing, P. Hartge, S. Wacholder, Sonya Baker, M. Berlin, M. McAdams, M. Timmerman, L. Brody, M. Tucker (1997)
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.The New England journal of medicine, 336 20
-
T Kirchhoff, J Satagopan, N Kauff (2004)
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancerJ Natl Cancer Inst, 96
-
C. Begg (2002)
On the use of familial aggregation in population-based case probands for calculating penetrance.Journal of the National Cancer Institute, 94 16
-
K Offit (2006)
BRCA mutation frequency and penetrance: new data, old debateJ Natl Cancer Inst, 98
-
D. Easton, D. Ford, D. Bishop (1995)
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.American journal of human genetics, 56 1
-
A. Hubert, Tamar Peretz, O. Manor, L. Kaduri, Naomi Wienberg, I. Lerer, M. Sagi, D. Abeliovich (1999)
The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer.American journal of human genetics, 65 3
-
O. Johannsson, N. Loman, T. Möller, U. Kristoffersson, Å. Borg, H. Olsson (1999)
Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.European journal of cancer, 35 8
-
Dena Miller, M. Weinstock (1994)
Nonmelanoma skin cancer in the United States: incidence.Journal of the American Academy of Dermatology, 30 5 Pt 1
-
H Risch, J McLaughlin, D Cole, B Rosen (2001)
Prevalence of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancerAm J Hum Genet, 68
-
R. Moslehi, R. Moslehi, W. Chu, B. Karlan, D. Fishman, H. Risch, A. Fields, D. Smotkin, Y. Ben-David, J. Rosenblatt, D. Russo, P. Schwartz, N. Tung, E. Warner, B. Rosen, J. Friedman, J. Brunet, S. Narod (2000)
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.American journal of human genetics, 66 4
-
B Niell, G Rennert, J Bonner, R Almog, L Tomsho, S Gruber (2004)
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancerJ Natl Cancer Inst, 96
-
S. Hahn, B. Greenhalf, I. Ellis, M. Sina‐Frey, H. Rieder, B. Korte, B. Gerdes, R. Kress, A. Ziegler, J. Raeburn, D. Campra, R. Grützmann, H. Rehder, M. Rothmund, W. Schmiegel, J. Neoptolemos, D. Bartsch (2003)
BRCA2 germline mutations in familial pancreatic carcinoma.Journal of the National Cancer Institute, 95 3
-
B. Niell, G. Rennert, J. Bonner, R. Almog, L. Tomsho, S. Gruber (2004)
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.Journal of the National Cancer Institute, 96 1
-
L. Kadouri, M. Temper, T. Grenader, D. Abeliovich, T. Hamburger, T. Peretz, M. Lotem (2008)
Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi originFamilial Cancer, 8
-
E Levy-Lahad, E Friedman (2007)
Cancer risks among BRCA1 and BRCA2 carriers: minireviewBritish J Cancer, 96
-
Deborah Thompson, D. Easton (2002)
Cancer Incidence in BRCA1 mutation carriers.Journal of the National Cancer Institute, 94 18
-
(1999)
Cancer risks in BRCA2 mutation carriersJ Natl Cancer Inst, 91
-
S. Edwards, Z. Kote-Jarai, J. Meitz, R. Hamoudi, Q. Hope, P. Osin, R. Jackson, C. Southgate, Rashmi Singh, A. Falconer, D. Dearnaley, A. Ardern-jones, A. Murkin, A. Dowe, J. Kelly, Sue Williams, R. Oram, Margaret Stevens, D. Teare, B. Ponder, S. Gayther, D. Easton, R. Eeles (2003)
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.American journal of human genetics, 72 1
-
J. Bermejo, K. Hemminki (2004)
Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.Annals of oncology : official journal of the European Society for Medical Oncology, 15 12
-
D. Berman, J. Costalas, D. Schultz, G. Grana, M. Daly, A. Godwin (1996)
A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.Cancer research, 56 15
-
Rodney Scott, C. Vajdic, B. Armstrong, C. Ainsworth, C. Meldrum, J. Aitken, A. Kricker (2002)
BRCA2 mutations in a population‐based series of patients with ocular melanomaInternational Journal of Cancer, 102
-
T. Kirchhoff, N. Kauff, N. Mitra, K. Nafa, Helen Huang, C. Palmer, T. Gulati, E. Wadsworth, S. Donat, M. Robson, N. Ellis, K. Offit (2004)
BRCA Mutations and Risk of Prostate Cancer in Ashkenazi JewsClinical Cancer Research, 10
-
P. Pharoah, A. Antoniou, J. Hopper, D. Easton (2003)
Re: On the use of familial aggregation in population-based case probands for calculating penetrance.Journal of the National Cancer Institute, 95 1
-
DR Easton, D Ford, DT Bishop (1995)
Breast and ovarian incidence in BRCA1-mutartion carriersAm J Hum Genet, 56
-
N. Loman, A. Bladström, O. Johannsson, Å. Borg, H. Olsson (2003)
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation statusBreast Cancer Research, 5
-
S Hahn, B Greenhalf, I Ellis, M Sina-Frey (2003)
BRCA2 germline mutations in familial pancreatic carcinomaJ Natl Cancer Inst, 95
-
M Brose, T Rebbeck, K Calzone (2002)
Cancer risk estimates for BRCA1 mutation carriers identified in a cancer risk evaluation programJ Natl Cancer Inst, 94
-
W Burke, MA Austin (2003)
Re: on the use of familial aggregation in population-based case probands for calculating penetranceJ Natl Cancer Inst, 95
-
K. Murphy, K. Brune, C. Griffin, Jennifer Sollenberger, G. Petersen, R. Bansal, R. Hruban, S. Kern (2002)
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.Cancer research, 62 13
-
C. Monnerat, A. Chompret, C. Kannengiesser, M. Avril, N. Janin, A. Spatz, J. Guinebretière, C. Marian, M. Barrois, F. Boitier, G. Lenoir, B. Paillerets (2007)
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanomaFamilial Cancer, 6
-
Helen Shih, K. Nathanson, S. Seal, N. Collins, Michael Stratton, T. Rebbeck, Barbara Weber (2000)
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 11
-
DE Goldgar, DF Easton, L Cannon-Albright, M Skolnick (1994)
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probandsJ Natl Cancer Inst, 86
-
K. Offit (2006)
BRCA mutation frequency and penetrance: new data, old debate.Journal of the National Cancer Institute, 98 23
-
E. Levy-Lahad, E. Friedman, E. Friedman (2007)
Cancer risks among BRCA1 and BRCA2 mutation carriersBritish Journal of Cancer, 96
-
J. Iscovich, M. Abdulrazik, C. Cour, A. Fischbein, J. Pe’er, D. Goldgar (2002)
Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patientsInternational Journal of Cancer, 98
-
P. Aretini, E. D'andrea, B. Pasini, A. Viel, R. Costantini, L. Cortesi, E. Ricevuto, S. Agata, R. Bisegna, M. Boiocchi, M. Caligo, L. Chieco‐Bianchi, G. Cipollini, R. Crucianelli, C. D'amico, M. Federico, C. Ghimenti, C. Giacomi, A. Nicolo, L. Puppa, S. Ferrari, C. Ficorella, D. Iandolo, S. Manoukian, P. Marchetti, F. Marroni, C. Menin, M. Montagna, L. Ottini, V. Pensotti, M. Pierotti, P. Radice, M. Santarosa, V. Silingardi, D. Turchetti, G. Bevilacqua, S. Presciuttini (2003)
Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified MutationBreast Cancer Research and Treatment, 81
-
A. Vazina, J. Baniel, Y. Yaacobi, A. Shtriker, D. Engelstein, I. Leibovitz, M. Zehavi, A. Sidi, Y. Ramon, T. Tischler, P. Livne, E. Friedman (2000)
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in IsraelBritish Journal of Cancer, 83
-
D. Goldgar, D. Easton, L. Cannon-Albright, M. Skolnick (1994)
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.Journal of the National Cancer Institute, 86 21
-
R. Chen-Shtoyerman, A. Figer, H. Fidder, P. Rath, L. Yeremin, S. Meir, E. Friedman, L. Theodor (2001)
The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patientsBritish Journal of Cancer, 84
-
D. Ford, D. Easton, D. Bishop, S. Narod, D. Goldgar (1994)
Risks of cancer in BRCA1-mutation carriersThe Lancet, 343
-
M. Brose, T. Rebbeck, K. Calzone, J. Stopfer, K. Nathanson, B. Weber (2002)
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.Journal of the National Cancer Institute, 94 18
-
H. Risch, J. McLaughlin, D. Cole, B. Rosen, L. Bradley, E. Kwan, E. Jack, D. Vesprini, G. Kuperstein, J. Abrahamson, I. Fan, B. Wong, S. Narod (2001)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.American journal of human genetics, 68 3
-
T. Kirchhoff, J. Satagopan, N. Kauff, Helen Huang, P. Kolachana, C. Palmer, H. Rapaport, K. Nafa, N. Ellis, K. Offit (2004)
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.Journal of the National Cancer Institute, 96 1
-
S. Thorlacius, J. Struewing, Patricia Hartage, G. Olafsdóttir, H. Sigvaldason, L. Tryggvadottir, S. Wacholder, H. Tulinius, J. Eyfjörd (1998)
Population-based study of risk of breast cancer in carriers of BRCA2 mutationThe Lancet, 352
-
D Thompson, DF Easton (2002)
Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriersJ Natl Cancer Inst, 94
-
A. Navaraj, Toshio Mori, W. El-Deiry (2005)
Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimersCancer Biology & Therapy, 4
-
J Iscovitch, M Abdulrazik, C Cour (2002)
Prevalence of the BRCA2 6174delT mutation in uveal melanoma patientsInt J Cancer, 98
-
G. Lal, Geoffrey Liu, Beverley Schmocker, P. Kaurah, H. Ozçelik, S. Narod, M. Redston, S. Gallinger (2000)
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.Cancer research, 60 2
-
D. Easton, L. Steele, P. Fields, W. Ormiston, D. Averill, P. Daly, R. McManus, S. Neuhausen, D. Ford, R. Wooster, L. Cannon-Albright, Michael Stratton, D. Goldgar (1997)
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.American journal of human genetics, 61 1
-
H. Olsson (1999)
Cancer risks in BRCA2 mutation carriers.Journal of the National Cancer Institute, 91 15
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Springer Science+Business Media B.V.
- Subject
- Biomedicine; Biomedicine general; Epidemiology; Human Genetics ; Cancer Research
- ISSN
- 1389-9600
- eISSN
- 1573-7292
- DOI
- 10.1007/s10689-010-9377-y
- pmid
- 20809262
- Publisher site
- See Article on Publisher Site
Abstract
BRCA1 and BRCA2 mutation carriers have elevated risks of breast and ovarian cancers. The risks for cancers at other sites remain unclear. Melanoma has been associated with BRCA2 mutations in some studies, however, few surveys have included non-melanoma skin cancer. We followed 2729 women with a BRCA1 or BRCA2 mutation for an average of 5.0 years. These women were asked to report new cases of cancer diagnosed in themselves or in their family. The risks of skin cancer were compared for probands with BRCA1 and BRCA2 mutations. Of 1779 women with a BRCA1 mutation, 29 developed skin cancer in the follow-up period (1.6%). Of the 950 women with a BRCA2 mutation, 28 developed skin cancer (3.0%) (OR = 1.83 for BRCA2 versus BRCA1; 95% CI 1.08–3.10; P = 0.02). The odds ratio for basal cell carcinoma was higher (OR = 3.8; 95% CI 1.5–9.4; P = 0.002). BRCA2 mutation carriers are at increased risk for skin cancer, compared with BRCA1 carriers, in particular for basal cell carcinoma.
Journal
Familial Cancer – Springer Journals
Published: Sep 1, 2010